Prevention of Contrast-Induced Nephropathy (CIN) in Interventional Radiology Practice

ABSTRACT

Contrast-induced nephropathy (CIN) is a widely recognized and clinically significant problem in patients undergoing an increasing number of minimally invasive procedures that require contrast administration. Contrast-induced nephropathy is the third most common cause of hospital-acquired renal failure and has significant prognostic implications on patient outcomes. Interventional practitioners are faced with challenging decisions regarding prophylaxis and patient management. The major risk factor for developing CIN is preexisting renal dysfunction, particularly in association with diabetes. Patients are considered to be at risk when estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eC_Cr) is less than 60. The cornerstone of prevention of CIN is appropriate risk stratification, intravenous hydration with normal saline or sodium bicarbonate, appropriate withholding of nephrotoxic medications, use of low or iso-osmolar contrast media, and various intraprocedural methods for iodinated contrast dose reduction. Although N-acetylcysteine administration is popular, it remains unproven. Practitioners must be familiar with prevention strategies and diagnosis of CIN to minimize its clinical impact.

Contrast-induced nephropathy - CIN - renal failure - contrast media - prevention

REFERENCES

• 1 Hou S H, Bushinsky D A, Wish J B, Cohen J J, Harrington J T. Hospital-acquired renal insufficiency: a prospective study.  Am J Med. 1983;  74(2) 243-248
• 2 Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency.  Am J Kidney Dis. 2002;  39(5) 930-936
• 3 Rihal C S, Textor S C, Grill D E et al.. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.  Circulation. 2002;  105(19) 2259-2264
• 4 Levy E M, Viscoli C M, Horwitz R I. The effect of acute renal failure on mortality. A cohort analysis.  JAMA. 1996;  275(19) 1489-1494
• 5 Ellis J H, Cohan R H. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies.  AJR Am J Roentgenol. 2009;  192(6) 1544-1549
• 6 Segal A J, Ellis J H et al.. ACR, Manual on Contrast Media: Version 6. 2008. Available at: http://www.acr.org/contrast-manual Accessed November 1, 2009
• 7 Gleeson T G, Bulugahapitiya S. Contrast-induced nephropathy.  AJR Am J Roentgenol. 2004;  183(6) 1673-1689
• 8 Kolonko A, Kokot F, Wiecek A. Contrast-associated nephropathy—old clinical problem and new therapeutic perspectives.  Nephrol Dial Transplant. 1998;  13(3) 803-806
• 9 Goldfarb S, McCullough P A, McDermott J, Gay S B. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.  Mayo Clin Proc. 2009;  84(2) 170-179
• 10 Katzberg R W, Lamba R. Contrast-induced nephropathy after intravenous administration: fact or fiction?.  Radiol Clin North Am. 2009;  47(5) 789-800, v , v
• 11 Newhouse J H, Kho D, Rao Q A, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity.  AJR Am J Roentgenol. 2008;  191(2) 376-382
• 12 Cramer B C, Parfrey P S, Hutchinson T A et al.. Renal function following infusion of radiologic contrast material. A prospective controlled study.  Arch Intern Med. 1985;  145(1) 87-89
• 13 Heller C A, Knapp J, Halliday J, O'Connell D, Heller R F. Failure to demonstrate contrast nephrotoxicity.  Med J Aust. 1991;  155(5) 329-332
• 14 Rao Q A, Newhouse J H. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis.  Radiology. 2006;  239(2) 392-397
• 15 Rudnick M R, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it.  Cleve Clin J Med. 2006;  73(1) 75-80 83-87
• 16 Schweiger M J, Chambers C E, Davidson C J et al.. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures.  Catheter Cardiovasc Interv. 2007;  69(1) 135-140
• 17 McCullough P A, Wolyn R, Rocher L L, Levin R N, O'Neill W W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.  Am J Med. 1997;  103(5) 368-375
• 18 Barrett B J, Parfrey P S. Clinical practice. Preventing nephropathy induced by contrast medium.  N Engl J Med. 2006;  354(4) 379-386
• 19 Benko A, Fraser-Hill M, Magner P Canadian Association of Radiologists et al. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.  Can Assoc Radiol J. 2007;  58(2) 79-87
• 20 Ellis J H, Cohan R H. Prevention of contrast-induced nephropathy: an overview.  Radiol Clin North Am. 2009;  47(5) 801-811, v , v
• 21 Rudnick M R, Goldfarb S, Wexler L et al.. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.  Kidney Int. 1995;  47(1) 254-261
• 22 McCullough P A, Sandberg K R. Epidemiology of contrast-induced nephropathy.  Rev Cardiovasc Med. 2003;  4(Suppl 5) S3-S9
• 23 Thomsen H S, Morcos S K. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT—a pooled analysis of two randomized trials.  Eur Radiol. 2009;  19(4) 891-897
• 24 Thomsen H S, Morcos S K. Radiographic contrast media.  BJU Int. 2000;  86(Suppl 1) 1-10
• 25 Morcos S K. Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media?.  Clin Radiol. 2009;  64(5) 468-472
• 26 Taliercio C P, Vlietstra R E, Ilstrup D M et al.. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography.  J Am Coll Cardiol. 1991;  17(2) 384-390
• 27 Manke C, Marcus C, Page A, Puey J, Batakis O, Fog A. Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers.  Acta Radiol. 2003;  44(6) 590-596
• 28 Justesen P, Downes M, Grynne B H, Lang H, Rasch W, Seim E. Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide.  Cardiovasc Intervent Radiol. 1997;  20(4) 251-256
• 29 Pugh N D, Sissons G R, Ruttley M S, Berg K J, Nossen J O, Eide H. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide.  Clin Radiol. 1993;  47(2) 96-99
• 30 Verow P, Nossen J O, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography.  Br J Radiol. 1995;  68(813) 973-978
• 31 Cigarroa R G, Lange R A, Williams R H, Hillis L D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease.  Am J Med. 1989;  86(6 Pt 1) 649-652
• 32 Freeman R V, O'Donnell M, Share D Blue Cross-Blue Shield of Michigan Cardiovascular Consortium (BMC2) et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose.  Am J Cardiol. 2002;  90(10) 1068-1073
• 33 Laskey W K, Jenkins C, Selzer F NHLBI Dynamic Registry Investigators et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.  J Am Coll Cardiol. 2007;  50(7) 584-590
• 34 Mueller C, Buerkle G, Buettner H J et al.. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.  Arch Intern Med. 2002;  162(3) 329-336
• 35 Merten G J, Burgess W P, Gray L V et al.. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;  291(19) 2328-2334
• 36 Brar S S, Shen A Y, Jorgensen M B et al.. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.  JAMA. 2008;  300(9) 1038-1046
• 37 Hogan S E, L'Allier P, Chetcuti S et al.. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis.  Am Heart J. 2008;  156(3) 414-421
• 38 Navaneethan S D, Singh S, Appasamy S, Wing R E, Sehgal A R. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.  Am J Kidney Dis. 2009;  53(4) 617-627
• 39 From A M, Bartholmai B J, Williams A W, Cha S S, Pflueger A, McDonald F S. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic.  Clin J Am Soc Nephrol. 2008;  3(1) 10-18
• 40 Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.  N Engl J Med. 2000;  343(3) 180-184
• 41 Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy.  Clin J Am Soc Nephrol. 2008;  3(1) 281-287
• 42 Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.  Trials. 2009;  10 45
• 43 Gonzales D A, Norsworthy K J, Kern S J et al.. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.  BMC Med. 2007;  5 32
• 44 Marenzi G, Assanelli E, Marana I et al.. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.  N Engl J Med. 2006;  354(26) 2773-2782
• 45 Vaitkus P T, Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses.  Am Heart J. 2007;  153(2) 275-280
• 46 Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer B K. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable.  J Am Soc Nephrol. 2004;  15(2) 407-410
• 47 Poletti P A, Saudan P, Platon A et al.. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.  AJR Am J Roentgenol. 2007;  189(3) 687-692
• 48 Baker C S, Wragg A, Kumar S, De Palma R, Baker L R, Knight C J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.  J Am Coll Cardiol. 2003;  41(12) 2114-2118
• 49 Vogt B, Ferrari P, Schönholzer C et al.. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.  Am J Med. 2001;  111(9) 692-698
• 50 Marenzi G, Marana I, Lauri G et al.. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.  N Engl J Med. 2003;  349(14) 1333-1340